Standards and Schedules

HRS div. 1, tit. 19, ch. 329, pt. II

in effect

HRS §329-11 Authority to schedule controlled substances

329-11. Authority to schedule controlled substances (a) Annually, upon the convening of each regular session of the state legislature, the department of public safety shall report to the legislature additions, deletions, or revisions in the schedules of substances enumerated in sections 329-14, 329-16, 329-18, 329-20, and 329-22, and any other recommendations that it deems necessary. Three months prior to the convening of each regular session, the department of public safety shall post public notice, at the state capitol and in the office of the lieutenant governor for public inspection, of the department's recommendations to the legislature concerning any additions, deletions, or revisions in these schedules; provided that the posting shall not be required if official notice has been received that the substance has been added, deleted, or rescheduled as a controlled substance under federal law. In making a determination regarding a substance, the department of public safety shall assess the degree of danger or probable danger of the substance by considering the following: (1) The actual or probable abuse of the substance including: (A) Its history and current pattern of abuse; (B) The scope, duration, and significance of abuse; and (C) A judgment of the degree of actual or probable detriment that may result from the abuse of the substance; (2) The biomedical hazard of the substance including: (A) Its pharmacology: the effects and modifiers of effects of the substance; (B) Its toxicology: the acute and chronic toxicity, interaction with other substances whether controlled or not, and liability to psychic or physiological dependence; (C) Risk to public health and particular susceptibility of segments of the population; and (D) Existence of therapeutic alternatives for substances that are or may be used for medical purposes; (3) A judgment of the probable physical and social impact of widespread abuse of the substance; (4) Whether the substance is an immediate precursor of a substance already controlled under this part; and (5) The current state of scientific knowledge regarding the substance. (b) After considering the factors enumerated in subsection (a), the department of public safety shall make a recommendation to the legislature, specifying to what schedule the substance should be added, deleted, or rescheduled if it finds that the substance has a degree of danger or probable danger. The department of public safety may make its recommendation to the legislature prior to the submission of its annual report, in which case the department of public safety shall publish and give notice to the public of the recommendation. (c) If the legislature designates a substance as an immediate precursor, substances that are precursors of the controlled precursor shall not be subject to control solely because they are precursors of the controlled precursor. (d) If a substance is added, deleted, or rescheduled as a controlled substance under federal law and notice of the designation is given to the department of public safety, the department of public safety shall recommend that a corresponding change in Hawaii law be made. The department of public safety shall similarly designate the substance as added, deleted, or rescheduled under this chapter, after the expiration of thirty days from publication in the Federal Register of a final order, and this change shall have the effect of law. If a substance is added, deleted, or rescheduled under this subsection, the control shall be temporary and, if the next regular session of the state legislature has not made the corresponding changes in this chapter, the temporary designation of the added, deleted, or rescheduled substance shall be nullified. (e) The administrator may make an emergency scheduling by placing a substance into schedule I, II, III, IV, or V on a temporary basis, if the administrator determines the action is necessary to address or avoid a current or imminent danger to the health and safety of the public. In making the determination of whether to emergency schedule a substance, the administrator shall assess the degree of danger or probable danger of the substance by considering the following: (1) The actual or possible abuse of the substance including: (A) Its history and current pattern of abuse; (B) The scope, duration, and significance of abuse; and (C) A judgment of the degree of actual or possible detriment that may result from the abuse of the substance; and (2) The risk to public health. The department shall post a public notice thirty days prior to the effective date of the emergency scheduling action, at the state capitol, in the office of the lieutenant governor, and on the department's website for public inspection. If a substance is added or rescheduled under this subsection, the control shall be temporary and, if the next regular session of the state legislature has not enacted the corresponding changes in this chapter, the temporary designation of the added or rescheduled substance shall be nullified. [L 1972, c 10, pt of §1; am L 1987, c 113, §1; am L 1990, c 281, §10; am L 1997, c 280, §1 and c 356, §6; am L 2013, c 68, §1]

HRS §329-12 Nomenclature

329-12. Nomenclature The controlled substances listed or to be listed in the schedules in sections 329-14, 329-16, 329-18, 329-20, and 329-22 are included by whatever official, common, usual, chemical, or trade name designated. L 1972, c 10, pt of §1

HRS §329-13 Schedule I tests

329-13. Schedule I tests A substance shall be placed in schedule I if it has the highest degree of danger or probable danger according to the determination made pursuant to section 329-11. L 1972, c 10, pt of §1

HRS §329-14 Schedule I

329-14. Schedule I (a) The controlled substances listed in this section are included in schedule I. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide), its optical, positional, and geometric isomers, salts, and salts of isomers; (4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] (Other name: acryloylfentanyl); (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide); (6) Allylprodine; (7) Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM); (8) Alphameprodine; (9) Alphamethadol; (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine); (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide); (12) Benzethidine; (13) Benzylfentanyl (N-[1-benzyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and salts of isomers; (14) Betacetylmethadol; (15) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide); (16) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide); (17) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide); (18) Betameprodine; (19) Betamethadol; (20) Beta-methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide) (Other name: [beta]-methyl fentanyl); (21) Beta'-phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-phenyl fentanyl; 3-phenylpropanoyl fentanyl); (22) Betaprodine; (23) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide); (24) Clonitazene; (25) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); (26) Dextromoramide; (27) Diampromide; (28) Diethylthiambutene; (29) Difenoxin; (30) Dimenoxadol; (31) Dimepheptanol; (32) Dimethylthiambutene; (33) Dioxaphetyl butyrate; (34) Dipipanone; (35) Ethylmethylthiambutene; (36) Etonitazene; (37) Etoxeridine; (38) Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate); (39) 4-fluoroisobutyryl fentanyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other name: para-fluoroisobutyryl fentanyl); (40) 2'-fluoro ortho-fluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide) (Other name: 2'-fluoro 2-fluorofentanyl); (41) Furanyl fentanyl (N-(1-phenethylpiperidin-4-y1)-N-phenylfuran-2-carboxamide); (42) Furethidine; (43) Hydroxypethidine; (44) Ketobemidone; (45) Levomoramide; (46) Levophenacylmorphan; (47) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (48) 4'-methyl acetyl fentanyl (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide); (49) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide); (50) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide); (51) Morpheridine; (52) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); (53) Noracymethadol; (54) Norlevorphanol; (55) Normethadone; (56) Norpipanone; (57) Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide]; (58) Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide); (59) Ortho-fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide) (Other name: 2-fluorobutyryl fentanyl); (60) Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 2-fluorofentanyl); (61) Ortho-fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); (62) Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl acetylfentanyl); (63) Ortho-methyl methoxyacetyl fentanyl (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl methoxyacetyl fentanyl); (64) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); (65) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide; (66) Para-fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide); (67) Para-methylfentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 4-methylfentanyl); (68) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); (69) Phenadoxone; (70) Phenampromide; (71) Phenomorphan; (72) Phenoperidine; (73) Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide) (Other name: benzoyl fentanyl); (74) Piritramide; (75) Proheptazine; (76) Properidine; (77) Propiram; (78) Racemoramide; (79) Thenylfentanyl (N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and salts of isomers; (80) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide); (81) Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide) (Other names: 2-thiofuranyl fentanyl; thiophene fentanyl); (82) Tilidine; (83) Trimeperidine; and (84) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide). (c) Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Acetorphine; (2) Acetyldihydrocodeine; (3) Benzylmorphine; (4) Codeine methylbromide; (5) Codeine-N-Oxide; (6) Cyprenorphine; (7) Desomorphine; (8) Dihydromorphine; (9) Drotebanol; (10) Etorphine; (11) Heroin; (12) Hydromorphinol; (13) Methyldesorphine; (14) Methyldihydromorphine; (15) Morphine methylbromide; (16) Morphine methylsulfonate; (17) Morphine-N-Oxide; (18) Myrophine; (19) Nicocodeine; (20) Nicomorphine; (21) Normorphine; (22) Phoclodine; and (23) Thebacon. (d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Alpha-ethyltryptamine (AET); (2) 2,5-dimethoxy-4-ethylamphetamine (DOET); (3) 2,5-dimethoxyamphetamine (2,5-DMA); (4) 3,4-methylenedioxy amphetamine; (5) 3,4-methylenedioxymethamphetamine (MDMA); (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA); (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE); (8) 5-methoxy-3,4-methylenedioxy-amphetamine; (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA); (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus); (11) 3,4,5-trimethoxy amphetamine; (12) Bufotenine; (13) 4-methoxyamphetamine (PMA); (14) Diethyltryptamine; (15) Dimethyltryptamine; (16) 4-methyl-2,5-dimethoxy-amphetamine; (17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate); (18) Ibogaine; (19) Lysergic acid diethylamide; (20) Marijuana; (21) Parahexyl; (22) Mescaline; (23) Peyote; (24) N-ethyl-3-piperidyl benzilate; (25) N-methyl-3-piperidyl benzilate; (26) Psilocybin; (27) Psilocyn; (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy); (29) Ethylamine analog of phencyclidine (PCE); (30) Pyrrolidine analog of phencyclidine (PCPy, PHP); (31) Thiophene analog of phencyclidine (TPCP; TCP); (32) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion; (33) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion; (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers; (35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its optical isomers, salts, and salts of isomers; (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers; (37) Alpha-methyltryptamine (AMT); (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); (39) Salvia divinorum; (40) Salvinorin A; (41) Divinorin A; (42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT); (43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); (44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); (45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); (46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); (47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2); (48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); (49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); (50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); (51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); (52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5); (53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); (54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36); (55) N-ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one); (56) Alpha-pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-PHP; [alpha]-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); (57) 4-methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one); (58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one); (59) Alpha-pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one); (60) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-chloro-[alpha]-PVP; 4'-chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); and (61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine, MXE). (e) Depressants. Unless specifically excepted, the schedule shall include any material, compound, mixture, or preparation which contains any quantity of the substance: (1) Mecloqualone; (2) Methaqualone; (3) Etizolam (including its optical, positional, and geometric isomers, salts, and salts of isomers, where possible); or (4) Flualprazolam (including its optical, positional, and geometric isomers, salts, and salts of isomers, where possible). (f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: (1) Aminorex; (2) Cathinone; (3) 4,4'-dimethylaminorex (common name: 4,4'-DMAR); (4) Fenethylline; (5) Methcathinone; (6) 4-methylaminorex; (7) N-ethylamphetamine; (8) N,N-dimethylamphetamine; (9) Substituted cathinones, any compound, except bupropion or compounds listed under a different schedule, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways: (A) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents; (B) By substitution at the 3-position with an acyclic alkyl substituent; or (C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. Some other trade names: Mephedrone (2-methylamino-1-p-tolylpropan-1-one), also known as 4-methylmethcathinone (4-MMC), methylephedrone or MMCAT; Methylenedioxypyrovalerone (MDPV, MDPK); methylone or 3,4-methylenedioxymethcathinone; and 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); alpha-pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone, bk-MBDP); 4-fluoro-N-methylcathinone (4-FMC, flephedrone); 3-fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-pyrrolidinobutiophenone ([alpha]-PBP) and their optical, positional, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and (10) 1-(4-methoxyphenyl)-N-methylpropan-2-amine (Other names: para-methoxymethamphetamine; PMMA). (g) Cannabinoids. Unless specifically excepted or unless listed in another schedule, any of the following cannabinoids, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis plant), as well as synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; and Delta 3,4 cis or trans-tetrahydrocannabinol, and its optical isomers (since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions, are covered); (2) Naphthoylindoles; meaning any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (3) Naphthylmethylindoles; meaning any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (4) Naphthoylpyrroles; meaning any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent; (5) Naphthylmethylindenes; meaning any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent; (6) Phenylacetylindoles; meaning any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent; (7) Cyclohexylphenols; meaning any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with substitution at the 5-position of the phenolic ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not substituted in the cyclohexyl ring to any extent; (8) Benzoylindoles; meaning any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent; (9) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-naphthalenylmethanone (another trade name is WIN 55,212-2); (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Other trade names are: HU-210/HU-211); (11) Tetramethylcyclopropanoylindoles; meaning any compound containing a 3-tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent; (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: APINACA, AKB48); (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PB-22; QUPIC); (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-PB-22; 5F-PB-22); (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: AB-FUBINACA); (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: ADB-PINACA); (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: AB-CHMINACA); (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AB-PINACA); (19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone, and geometric isomers, salts, and salts of isomers (Other names: THJ-2201); (20) Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate, and geometric isomers, salts, and salts of isomers (Other names: FUB-AMB, Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, MMB-FUBINACA, AMB-FUBINACA); (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, and geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-AMB, 5-fluoro-AMP); (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AKB48 N-(5-fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl analog, 5F-APINACA); (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and geometric isomers, salts, and salts of isomers (Other names: STS-135, 5F-APICA; 5-fluoro-APICA); (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, and geometric isomers, salts, and salts of isomers (Other names: NM2201; CBL2201); (25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: MAB-CHMINACA and ADB-CHMINACA); (26) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (Other names: 5F-ADB, 5-fluoro-ADB, and 5F-MDMB-PINACA), its optical, positional, and geometric isomers, salts, and salts of isomers; (27) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: SGT-78; 4-CN-CUMYL BINACA; 4-CN-CUMYL-BUTINACA; CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-cyano-CUMYL-BUTINACA; CUMYL-4CN-BINACA); (28) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (Other name: 5F-AB-PINACA); (29) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (Other names: MMB-CHMICA; AMB-CHMICA); (30) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Other names: 5F-CUMYL-P7AICA); (31) Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA); (32) Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other name: 5F-EDMB-PINACA); (33) Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (Other names: 5F-MDMB-PICA; 5F-MDMB-2201); (34) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (Other names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL)); (35) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (Other names: 5F-CUMYL-PINACA; SGT-25); and (36) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other name: FUB-144). [L 1972, c 10, pt of §1; am L 1974, c 217, §1; am L 1977, c 116, §1; am L 1978, c 68, §2; am L 1979, c 194, §1; am L 1980, c 140, §1 and c 232, §16; am L 1984, c 166, §1; am L 1985, c 150, §1; am L 1986, c 214, §§2, 3; am L 1988, c 59, §1; am L 1990, c 138, §3; am L 1993, c 8, §1; am L 1995, c 122, §1; am L 1997, c 356, §1; am L 1999, c 252, §2; am L 2000, c 98, §1; am L 2001, c 203, §2; am L 2003, c 151, §§1, 2; am L 2008, c 119, §3; am L 2010, c 123, §1; am L 2011, c 73, §1; am L 2012, c 29, §1; am L 2013, c 48, §1; am L 2014, c 54, §1; am L 2015, c 195, §1; am L 2016, c 218, §§2, 3; am L 2017, c 155, §1; am L 2018, c 190, §1; am L 2020, c 27, §2 and c 70, §48; am L 2021, c 233, §1; am L 2022, c 106, §1; am L 2023, c 162, §1]

HRS §329-15 Schedule II tests

329-15. Schedule II tests A substance shall be placed in schedule II if it has a high degree of danger or probable danger according to the determination made pursuant to section 329-11. L 1972, c 10, pt of §1

HRS §329-16 Schedule II

329-16. Schedule II (a) The controlled substances listed in this section are included in schedule II. (b) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis: (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone, and their respective salts, but including the following: (A) Raw opium; (B) Opium extracts; (C) Opium fluid; (D) Powdered opium; (E) Granulated opium; (F) Codeine; (G) Ethylmorphine; (H) Etorphine hydrochloride; (I) Hydrocodone; (J) Hydromorphone; (K) Metopon; (L) Morphine; (M) Oxycodone; (N) Oxymorphone; (O) Thebaine; (P) Dihydroetorphine; (Q) Oripavine; and (R) Tincture of opium; (2) Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1), but not including the isoquinoline alkaloids of opium; (3) Opium poppy and poppy straw; (4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocanized coca leaves or extractions which do not contain cocaine or ecgonine; cocaine or any salt or isomer thereof; and (5) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form that contains the phenanthrene alkaloids of the opium poppy). (c) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: (1) Alfentanil; (2) Alphaprodine; (3) Anileridine; (4) Bezitramide; (5) Bulk Dextropropoxyphene (nondosage form); (6) Carfentanil; (7) Dihydrocodeine; (8) Diphenoxylate; (9) Fentanyl; (10) Isomethadone; (11) Levo-alphacetylmethadol (LAAM); (12) Levomethorphan; (13) Levorphanol; (14) Metazocine; (15) Methadone; (16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane; (17) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic acid; (18) Oliceridine, including the free base form, and its salts, to include the fumarate salt, by definition; (19) Pethidine (Meperidine); (20) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine; (21) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate; (22) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid; (23) Phenazocine; (24) Piminodine; (25) Racemethorphan; (26) Racemorphan; (27) Remifentanil; (28) Sufentanil; (29) Tapentadol; and (30) Thiafentanil. (d) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: (1) Amobarbital; (2) Glutethimide; (3) Pentobarbital; (4) Phencyclidine; (5) Secobarbital. (e) Stimulants. Any material, compound, mixture, or preparation which contains any quantity of the following substances having a danger or probable danger associated with a stimulant effect on the central nervous system: (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers; (2) Any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers; (3) Phenmetrazine and its salts; (4) Methylphenidate; and (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers. (f) Immediate precursor. Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances: (1) Immediate precursor to amphetamine and methamphetamine: (A) Phenylacetone, phenyl-2-propanone(P2P), benzyl methyl ketone, methyl benzyl ketone; (2) Immediate precursors to phencyclidine (PCP): (A) 1-phenylcyclohexylamine; or (B) 1-piperidinocyclohexanecarbonitrile(PCC); or (3) Immediate precursor to Fentanyl: (A) 4-anilino-N-phenethyl-4-piperidine (ANPP); or (B) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl). (g) Hallucinogenic substances, unless listed in another schedule, shall include: (1) Nabilone; and (2) Dronabinol (-)-delta-9-trans tetrahydrocannabinol in an oral solution in a drug product approved for marketing by the United States Food and Drug Administration. [L 1972, c 10, pt of §1 and am c 114, §2(2); am L 1974, c 217, §2; am L 1975, c 26, §1; am L 1978, c 68, §3; am L 1979, c 194, §2; am L 1981, c 125, §§1, 2; am L 1984, c 166, §2; am L 1985, c 150, §2; am L 1987, c 203, §1; am L 1988, c 59, §2; am L 1990, c 138, §4; am L 1991, c 159, §7; am L 1995, c 122, §2; am L 1997, c 356, §2; am L 2000, c 98, §§2, 3; am L 2001, c 203, §3; am L 2002, c 165, §1; am L 2003, c 151, §3; am L 2008, c 119, §4; am L 2009, c 117, §§1, 2; am L 2010, c 123, §2; am L 2011, c 73, §2; am L 2012, c 29, §2; am L 2013, c 48, §2; am L 2017, c 155, §2; am L 2018, c 152, §1 and c 190, §2; am L 2021, c 233, §2; am L 2022, c 106, §2]

HRS §329-17 Schedule III tests

329-17. Schedule III tests A substance shall be placed in schedule III if the substance has a degree of danger or probable danger less than the substances listed in schedules I and II according to the determination made pursuant to section 329-11. L 1972, c 10, pt of §1

HRS §329-18 Schedule III

329-18. Schedule III (a) The controlled substances listed in this section are included in schedule III. (b) Stimulants. Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substance listed in schedule II, and any other drug of the quantitative composition or which is the same except that it contains a lesser quantity of controlled substances; (2) Benzphetamine; (3) Chlorphentermine; (4) Clortermine; (5) Mazindol; (6) Phendimetrazine. (c) Depressants. Unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances having a depressant effect on the central nervous system: (1) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule; (2) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository; (3) Any substance that contains any quantity of a derivative of barbituric acid or any salt thereof, including the substance butalbital; (4) Chlorhexadol; (5) Embutramide (Tributame); (6) Ketamine, its salts, isomers, and salts of isomers, also known as (+ or -)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone; (7) Lysergic acid; (8) Lysergic acid amide; (9) Methyprylon; (10) Sulfondiethylmethane; (11) Sulfonethylmethane; (12) Sulfonmethane; (13) Tiletamine/Zolazepam (Telazol, 2-(ethylamino)-2-(-thienyl)-cyclohexanone, flupyrazapon) or any salts thereof; (14) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers that are contained in a drug product for which an application has been approved under section 505 of the federal Food, Drug, and Cosmetic Act; (15) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-l,2-dihydropyridin-3-yl)benzonitrile], including its salts, isomers, and salts of isomers; and (16) Alfaxalone 5[alpha]-pregnan-3[alpha]-ol-11,20-dione, including its salts, isomers, and salts of isomers. (d) Nalorphine. (e) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts, or alkaloid, in limited quantities as set forth below: (1) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium; (2) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (3) Not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (4) Not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts; (5) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts; (6) Not more than 50 milligrams of morphine or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; and (7) Buprenorphine. (f) [Subsection effective until December 31, 2023. For subsection effective January 1, 2024, see below.] The department of public safety may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in subsections (b) and (c) from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system. (f) [Subsection effective January 1, 2024. For subsection effective until December 31, 2023, see above.] The department of law enforcement may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in subsections (b) and (c) from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system. (g) Any anabolic steroid. The term "anabolic steroid" means any drug or hormonal substance chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promotes muscle growth, and includes: (1) Boldenone; (2) Clostebol (4-Chlorotestosterone); (3) Dehydrochlormethyltestosterone; (4) Dihydrotestosterone (4-dihydrotestosterone); (5) Drostanolone; (6) Ethylestrenol; (7) Fluoxymesterone; (8) Formebolone (Formyldienolone); (9) Mesterolone; (10) Methandranone; (11) Methandriol; (12) Methandrostenolone (Methandienone); (13) Methenolone; (14) Methyltestosterone; (15) Mibolerone; (16) Nandrolone; (17) Norethandrolone; (18) Oxandrolone; (19) Oxymesterone; (20) Oxymetholone; (21) Stanolone (Dihydrotestosterone); (22) Stanozolol; (23) Testolactone; (24) Testosterone; (25) Trenbolone; (26) 3[beta], 17-dihydroxy-5a-androstane; (27) 3[alpha], 17[beta]-dihydroxy-5a-androstane; (28) 5[alpha]-androstan-3, 17-dione; (29) 1-androstenediol (3[beta], 17[beta]-dihydroxy-5[alpha]-androst-1-ene); (30) 1-androstenediol (3[alpha], 17[beta]-dihydroxy-5[alpha]-androst-1-ene); (31) 4-androstenediol (3[beta], 17[beta]-dihydroxy-androst-4-ene); (32) 5-androstenediol (3[beta], 17[beta]-dihydroxy-androst-5-ene); (33) 1-androstenedione ([5[alpha]]-androst-1-en-3, 17-dione); (34) 4-androstenedione (androst-4-en-3, 17-dione); (35) 5-androstenedione (androst-5-en-3, 17-dione); (36) Bolasterone (7[alpha], 17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one); (37) Calusterone (7[beta], 17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one); (38) [Delta]1-dihydrotestosterone (a.k.a. '1-testosterone') (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); (39) Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan); (40) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one; (41) 4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-3-one); (42) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxy-estr-4-en-3-one); (43) Mesterolone (1[alpha]methyl-17[beta]-hydroxy-[5[alpha]]-androstan-3-one); (44) Methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one); (45) Methandriol (17[alpha]-methyl-3[beta], 17[beta]-dihydroxyandrost-5-ene); (46) Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); (47) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-androstane; (48) 17[alpha]-methyl-3[alpha], 17[beta]-dihydroxy-5a-androstane; (49) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxyandrost-4-ene; (50) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one); (51) Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4, 9(10)-dien-3-one); (52) Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4, 9-11-trien-3-one); (53) 17[alpha]-methyl-[Delta] 1-dihydrotestosterone (17b [beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-1-testosterone'); (54) 19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-4-ene); (55) 19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-4-ene); (56) 19-nor-5-androstenediol (3[beta], 17[beta]-dihydroxyestr-5-ene); (57) 19-nor-5-androstenediol (3[alpha], 17[beta]-dihydroxyestr-5-ene); (58) 19-nor-4-androstenedione (estr-4-en-3, 17-dione); (59) 19-nor-5-androstenedione (estr-5-en-3, 17-dione); (60) Norbolethone (13[beta], 17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one); (61) Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one); (62) Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one); (63) Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3-one); (64) Tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-17[beta]-hydroxygon-4, 9, 11-trien-3-one); (65) Desoxymethyltestosterone (17a-methyl-5a-androst-2-en-17-ol, madol); (66) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione); (67) Boldione (Androsta-1,4-diene-3,17-dione); (68) Methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androstan-17beta-ol-3-one); (69) Prostanozol (17 beta-hydroxy-5 alpha-androstano[3,2-c]pryazole; and (70) Any salt, ester, or isomer of a drug or substance described or listed in this subsection, if that salt, ester, or isomer promotes muscle growth, except the term "anabolic steroid" does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for nonhuman administration. If any person prescribes, dispenses, or distributes an anabolic steroid intended for administration to nonhuman species for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph. (h) Hallucinogenic substances, unless listed in another schedule, shall include Dronabinol (synthetic), in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product. [L 1972, c 10, pt of §1 and am c 114, §2(1); am L 1974, c 217, §3; am L 1975, c 26, §2; am L 1977, c 116, §2; am L 1978, c 68, §4; am L 1988, c 59, §3; am L 1990, c 281, §10; am L 1991, c 159, §8; am L 1992, c 151, §1; am L 1995, c 122, §3; am L 1997, c 356, §§3, 4; am L 2000, c 98, §4; am L 2001, c 203, §4; am L 2003, c 151, §4; am L 2004, c 193, §2; am L 2008, c 186, §3; am L 2009, c 117, §3; am L 2011, c 73, §3; am L 2013, c 48, §3; am L 2014, c 54, §2; am L 2015, c 195, §2; am L 2022, c 278, §17]

HRS §329-19 Schedule IV tests

329-19. Schedule IV tests A substance shall be placed in schedule IV if the substance has a degree of danger or probable danger less than the substances listed in schedule III according to the determination made pursuant to section 329-11. L 1972, c 10, pt of §1

HRS §329-20 Schedule IV

329-20. Schedule IV (a) The controlled substances listed in this section are included in schedule IV. (b) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, esters, ethers, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, that has a degree of danger or probable danger associated with a depressant effect on the central nervous system: (1) Alprazolam; (2) Barbital; (3) Brexanolone; (4) Bromazepam; (5) Butorphanol; (6) Camazepam; (7) Carisoprodol; (8) Chloral betaine; (9) Chloral hydrate; (10) Chlordiazepoxide; (11) Clobazam; (12) Clonazepam; (13) Clorazepate; (14) Clotiazepam; (15) Cloxazolam; (16) Daridorexant; (17) Delorazepam; (18) Diazepam; (19) Dichloralphenazone (Midrin); (20) Estazolam; (21) Ethchlorvynol; (22) Ethinamate; (23) Ethyl loflazepate; (24) Fludiazepam; (25) Flunitrazepam; (26) Flurazepam; (27) Fospropofol (Lusedra); (28) Halazepam; (29) Haloxazolam; (30) Ketazolam; (31) Lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide); (32) Loprazolam; (33) Lorazepam; (34) Lormetazepam; (35) Mebutamate; (36) Medazepam; (37) Meprobamate; (38) Methohexital; (39) Methylphenobarbital (mephorbarbital); (40) Midazolam; (41) Nimetazepam; (42) Nitrazepam; (43) Nordiazepam; (44) Oxazepam; (45) Oxazolam; (46) Paraldehyde; (47) Petrichloral; (48) Phenobarbital; (49) Pinazepam; (50) Prazepam; (51) Quazepam; (52) Remimazolam; (53) Suvorexant; (54) Temazepam; (55) Tetrazepam; (56) Triazolam; (57) Zaleplon; (58) Zolpidem; and (59) Zopiclone (Lunesta). (c) Fenfluramine. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible: Fenfluramine. (d) Stimulants. Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Cathine ((+)-norpseudoephedrine); (2) Diethylpropion; (3) Fencamfamin; (4) Fenproporex; (5) Lorcaserin; (6) Mazindol; (7) Mefenorex; (8) Modafinil; (9) Pemoline (including organometallic complexes and chelates thereof); (10) Phentermine; (11) Pipradrol; (12) Serdexmethylphenidate; (13) Sibutramine; (14) Solriamfetol; and (15) SPA (1-dimethylamino-1,2-diphenylethane, lefetamine). (e) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its optical isomers and its salts, isomers, and salts of isomers: (1) Pentazocine; and (2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid. (f) [Subsection effective until December 31, 2023. For subsection effective January 1, 2024, see below.] The department of public safety may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection (b) or any stimulant listed in subsection (d) from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant or stimulant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the degree of danger or probable danger of the substances which have a depressant or stimulant effect on the central nervous system. (f) [Subsection effective January 1, 2024. For subsection effective until December 31, 2023, see above.] The department of law enforcement may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection (b) or any stimulant listed in subsection (d) from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant or stimulant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the degree of danger or probable danger of the substances which have a depressant or stimulant effect on the central nervous system. (g) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: (1) Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit; (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane); and (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). [L 1972, c 10, pt of §1; am L 1973, c 184, §1; am L 1974, c 217, §4; am L 1977, c 116, §3; am L 1978, c 68, §5; am L 1979, c 194, §3; am L 1980, c 140, §2; am L 1985, c 150, §3; am L 1987, c 203, §2; am L 1990, c 281, §10; am L 1993, c 9, §1; am L 1995, c 122, §4; am L 2000, c 98, §5; am L 2001, c 203, §5; am L 2002, c 165, §2; am L 2003, c 151, §5; am L 2006, c 171, §1; am L 2008, c 119, §5; am L 2010, c 123, §3; am L 2014, c 54, §3; am L 2015, c 195, §3; am L 2016, c 218, §4; am L 2021, c 233, §3; am L 2022, c 106, §3 and c 278, §17; am L 2023, c 162, §2]

HRS §329-21 Schedule V tests

329-21. Schedule V tests A substance shall be placed in schedule V if it has a degree of danger or probable danger less than the substances listed in schedule IV according to the determination made pursuant to section 329-11. L 1972, c 10, pt of §1

HRS §329-22 Schedule V

329-22. Schedule V (a) The controlled substances listed in this section are included in schedule V. (b) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation, valuable medicinal qualities other than those possessed by the narcotic drug alone: (1) Not more than 200 milligrams of codeine, or any of its salts, per 100 milliliters or per 100 grams; (2) Not more than 100 milligrams of dihydrocodeine, or any of its salts, per 100 milliliters or per 100 grams; (3) Not more than 100 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or per 100 grams; (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit; (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams; and (6) Not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit. (c) Stimulants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers. (d) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers: (1) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (Other names: BRV; UCB-34714; Briviact) and its salts; (2) Ganaxolone (3[alpha]-hydroxy-3[beta]-methyl-5[alpha]-pregnan-20-one); (3) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide], (Vimpat); (4) Lasmiditan (2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide); and (5) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]. [L 1972, c 10, pt of §1; am L 1978, c 68, §6; am L 1985, c 150, §4; am L 2003, c 151, §6; am L 2008, c 119, §6; am L 2010, c 123, §4; am L 2017, c 155, §3; am L 2019, c 95, §1; am L 2021, c 233, §4; am L 2022, c 106, §4; am L 2023, c 162, §3]

HRS §329-23 Republishing and distribution of schedules. [Section effective until December 31, 2023

329-23. Republishing and distribution of schedules. [Section effective until December 31, 2023 For section effective January 1, 2024, see below.] (a) The department of public safety shall make available to the public on the department's website the schedules annually or more often, as may be necessary to update the schedules. (b) The department of public safety shall publicly announce and, in addition, shall make available to the public copies of any changes to the schedules as such changes are made. [L 1972, c 10, pt of §1; am L 1979, c 194, §4; am L 1990, c 281, §10; am L 2016, c 218, §5]

Source: Hawaii State Legislature (capitol.hawaii.gov), via Internet Archive capturesURL: http://www.capitol.hawaii.gov/hrscurrent/Vol06_Ch0321-0344/HRS0329/HRS_0329-.htmFetched: 11/10/2026